Carolinas HealthCare System

Research and Clinical Trials


Brief Description Principal Investigator
The primary objective of this study is to evaluate safety and tolerability and select a recommended Phase 2 dose (RP2D) of ADXS31-164 in subjects with solid tumors that express HER2 Tan, Antoinette Roslyn 
To evaluate progression free survival (PFS) with nab-paclitaxel as maintenance treatment after response or stable disease (SD) with nab-paclitaxel plus carboplatin in subjects with squamous cell NSCLC. Mileham, Kathryn Finch 
To assess the safety and tolerability of weekly continous nab-paclitaxel (Abraxane┬«) vs. with 1 week break in combination with Carboplatin as 1st line treatment for advanced NSCLC in elderly subjects >70 years old). Haggstrom, Daniel Ernest 
Celgene ABI-007-ST-001 Carrizosa, Daniel Ricardo 
The primary objective of this study is to evaluate the safety and tolerability of LY2835219 when administered orally in combination with multiple single-agent options to patients with Stage IV non-small cell lung cancer (NSCLC) using Common Terminology Criteria for Adverse Events (CTCAE version 4.0, NCI 2009). The secondary objectives of the study are to determine the pharmacokinetics (PK) of LY2835219 when given in combination with multiple single-agent options; to document the antitumor activ Kim, Edward Sanghyun 
To assess the safety and tolerability of the combination of PEGPH20 with docetaxel (PDoc).
To determine the recommended Phase 2 dose (RP2D) of PDoc.
To determine the recommended Phase 2 schedule of PDoc in subjects whose tumors have high levels of HA (high-HA).
Haggstrom, Daniel Ernest 
Primary Objectives to include: PrimaryTo determine safe and biologically active Phase 2 doses (recommended Phase 2 doses [RP2D]) for JNJ-42756493 in the Part 1 Dose-Escalation Phase; and to evaluate the feasibility of treating a molecularly-defined subset of subjects with non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC), breast cancer, and all-comers with solid tumors with JNJ-42756493 at the RP2Ds (Part 3 and 4; Dose-Expansion Phases).
Secondary Objectives to include: To evalu
Chai, Seungjean 
To assess the response rate of the combination of carboplatin and abraxane in patients with advanced non-small cell lung cancer (NSCLC).
To assess the disease control rate, duration of response, duration of disease control, overall survival, progression-free survival, and the safety and toxicity profile with this regimen.
To assess broad molecular profiling.
Mileham, Kathryn Finch 
This registry is intended to measure the effect of myPlan Lung Cancer? test has on influencing treatment decisions of Oncologists when added to standard clinical-pathological parameters in patients with early stage NSCLC.

Mileham, Kathryn Finch 
About Carolinas HealthCare System
Who We Are
Community Benefit
Corporate Financial Information
Diversity & Inclusion
Annual Report
Patient Links
Pay Your Bill
Hospital Pre-Registration
Patient Rights
Financial Assistance
Quality & Value Reports
Join Carolinas HealthCare System
Physician Careers

For Employees
Carolinas Connect
Connect with Us
Watch Carolinas HealthCare on YoutubeFollow Carolinas HealthCare on TwitterLike Carolinas HealthCare on FacebookContact Carolinas HealthCareJoin Carolinas HealthCare on LinkedInGo to our mobile website.